Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)-Reference-Cited by-同舟云学术

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)

Published:2022-12 Issue:8 Volume:23 Page:e545-e549
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Guisier Florian^ORCID,Descourt Renaud,Babey Helene,Huchot Eric,Falchero Lionel,Veillon Remi,Cortot Alexis B.,Tissot Claire,Chouaid Christos,Decroisette Chantal

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. cMET Exon 14 skipping: from the structure to the clinic;Van Der Steen;J Thorac Oncol,2016

2. Targeting the MET-signaling pathway in non-small-cell lung cancer: evidence to date;Bylicki;Onco Targets Ther,2020

3. Tepotinib in non-small-cell lung cancer with;Paik;N Engl J Med,2020

4. Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer;Wolf;N Engl J Med,2020

5. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers;Sabari;Ann Oncol,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MET Oncogene Targeting for Cancer Immunotherapy;International Journal of Molecular Sciences;2024-06-01

2. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations;European Journal of Cancer;2024-03

3. Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations;JTO Clinical and Research Reports;2023-10

4. Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways;Cancers;2023-06-27

5. Pembrolizumab;Reactions Weekly;2023-04-22